Treatment

semaglutide clinical trials

Active studies that list semaglutide as an intervention or treatment.

20active studies

11recruiting now

9countries represented

12largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of BGM0504 in Early T2DM With Obesity

Type 2 Diabetes (T2DM)Condition

BGM0504, semaglutideTreatment

China1 locations

BrightGene Bio-Medical Technology Co., Ltd.Sponsor

Updated 2026-08-04 · NCT07743983See eligibility →

Recruiting nowPhase 2, Phase 3

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Menopause, Menopause Hot FlashesCondition

Metformin, semaglutideTreatment

United States3 locations

University of Colorado, DenverSponsor

Updated 2026-07-21 · NCT06975111See eligibility →

Recruiting nowNot applicable

Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin

Diabetes MellitusCondition

semaglutideTreatment

Argentina2 locations

Hospital Italiano de Buenos AiresSponsor

Updated 2026-06-02 · NCT07621419See eligibility →

Recruiting nowPhase 2

Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

Cannabis Use Disorder, Cannabis Use DisordersCondition

semaglutide, PlaceboTreatment

Denmark1 locations

Anders Fink-Jensen, MD, DMSciSponsor

Updated 2026-05-14 · NCT07523633See eligibility →

Recruiting nowPhase 4

The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM), SemaglutideCondition

semaglutide, caloric restrictionTreatment

China1 locations

Second Affiliated Hospital of Nanchang UniversitySponsor

Updated 2026-04-02 · NCT07272343See eligibility →

Recruiting nowPhase 2

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

Alcohol Use Disorder (AUD), HIVCondition

semaglutideTreatment

United States1 locations

Yale UniversitySponsor

Updated 2026-03-24 · NCT07040592See eligibility →

Recruiting nowNot applicable

Probiotic Intervention on Body Weight

Obesity, HomeostasisCondition

General lifestyle and nutritional education, Energy-restricted nutritional and lifestyle interventionTreatment

China1 locations

Chinese Academy of SciencesSponsor

Updated 2026-03-17 · NCT06989177See eligibility →

Recruiting nowNot applicable

Protein Supplementation Intervention on Body Weight

Obesity, Weight LossCondition

General lifestyle and nutritional education, Calorie-restricted balanced dietTreatment

China1 locations

Chinese Academy of SciencesSponsor

Updated 2026-03-17 · NCT06989203See eligibility →

Recruiting nowPhase 4

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

Bipolar I Disorder, Bipolar II DisorderCondition

Group Therapy Program, semaglutideTreatment

United States1 locations

Mayo ClinicSponsor

Updated 2026-03-11 · NCT07213466See eligibility →

Recruiting nowPhase 4

GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

T2DM (Type 2 Diabetes Mellitus)Condition

semaglutide, Standard Treatment (Guideline-Based)Treatment

Italy2 locations

Federico II UniversitySponsor

Updated 2026-01-02 · NCT07314684See eligibility →

Recruiting nowPhase 3

Effect of Semaglutide in Patients With Psoriasis and Obesity

Psoriasis (PsO), Obesity and OverweightCondition

semaglutideTreatment

Hong Kong1 locations

The University of Hong KongSponsor

Updated 2025-05-13 · NCT06937060See eligibility →

Opening soonPhase 4

Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes

Type 2 Diabetes, Cognitive Decline in Older AdultsCondition

semaglutide, Moderate-Intensity Resistance ExerciseTreatment

Canada1 locations

Western University, CanadaSponsor

Updated 2026-08-20 · NCT07485062See eligibility →

Opening soonPhase 4

Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss

Class I/II ObesityCondition

semaglutideTreatment

Canada1 locations

Alain DagherSponsor

Updated 2026-06-26 · NCT07592546See eligibility →

Opening soonPhase 4

DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

Cardiovascular DiseasesCondition

semaglutide, TirzepatideTreatment

United Kingdom1 locations

Cambridge University Hospitals NHS Foundation TrustSponsor

Updated 2026-03-19 · NCT07483801See eligibility →

Opening soonNot applicable

Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH)Condition

semaglutide, DietTreatment

Canada1 locations

Institut universitaire de cardiologie et de pneumologie de Québec, University LavalSponsor

Updated 2025-01-08 · NCT06764056See eligibility →

Invitation onlyNot applicable

A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea

Obesity and OverweightCondition

semaglutideTreatment

South Korea8 locations

Novo Nordisk A/SSponsor

Updated 2025-06-12 · NCT07018544See eligibility →

Invitation onlyPhase 4

Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

Diabetes Mellitus, Cardiovascular DiseasesCondition

semaglutide, MetforminTreatment

China1 locations

China-Japan Friendship HospitalSponsor

Updated 2025-05-07 · NCT06959784See eligibility →

Active, not recruitingPhase 2

A Study of CS060380 Tablets in Patients With MASH and Obesity

Metabolic Dysfunction-associated Steatohepatitis (MASH), ObesityCondition

semaglutide, CS060380Treatment

China12 locations

Cascade Pharmaceuticals, IncSponsor

Updated 2026-08-10 · NCT07466017See eligibility →

Active, not recruitingPhase 3

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Condition

IBI362, semaglutideTreatment

China1 locations

Innovent Biologics (Suzhou) Co. Ltd.Sponsor

Updated 2026-05-12 · NCT06884293See eligibility →

Active, not recruitingPhase 3

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)Condition

GZR18, semaglutideTreatment

China1 locations

Gan & Lee Pharmaceuticals.Sponsor

Updated 2025-11-25 · NCT06778967See eligibility →

Related treatments

Placebo421 Tirzepatide119 Semaglutide91 Control30 Exercise27 Orforglipron21

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.